Mankind Pharma, India’s fourth largest pharmaceutical company, announced its consolidated financial results for the second quarter and six months ended 30th September 2024.

The company has posted net profit of Rs. 659 crore in Q2 FY25 as compared to Rs. 511 crore in Q2 FY24, reflecting a growth of 30 per cent. The company posted net profit of Rs. 543 crore in Q1 FY25.  Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24. Revenue from Operations was Rs. 2,893 crore in Q1 FY25.

For the Half Year ended Sept. 30, 2024, Mankind Pharma has posted net profit of Rs. 1,202 crore as compared to Rs. 1,005 crore in H1 FY24. Revenue from Operations stood at Rs. 5,970 crore as compared to Rs. 5,287 crore in H1 FY24.

Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said: “We are pleased to report steady revenue growth of 13.6% YoY with strong EBITDA margins of 27.7%, driven by recovery in volume, continued outperformance in chronic segment and operating leverage.

“OTC business has been carved out to a WOS2 of Mankind Pharma. From Q3, this business has embarked on the journey towards its next phase of growth. Our acquisition of BSV, perfectly aligns with our vision to expand into high entry barrier portfolio with #1 player in the gynaecology segment, leadership in certain critical care products and further enhance our R&D capabilities.

“Multiple growth levers – resilient base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV. Together, these levers will propel our growth journey ahead.”